Chinese artificial intelligence (AI)-based microbiome drug developer Xbiome has completed a new funding round led by the country’s venture capital firm Gaorong Capital and a Shenzhen-based investment company, according to a statement released on Monday.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!Register Now
Already have an account or paid subscription?